Atumelnant

DRUG5 trials

Sponsors

Crinetics Pharmaceuticals Inc.

Conditions

Classic Congenital Adrenal HyperplasiaCongenital Adrenal HyperplasiaCushing DiseaseCushing SyndromeEctopic ACTH SyndromeHealthy Volunteers

Phase 1

A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome

Active, not recruitingNCT05804669

Crinetics Pharmaceuticals Inc.Cushing Disease, Cushing Syndrome, Ectopic ACTH Syndrome

Start: 2023-10-12End: 2026-10-01Updated: 2026-08-19

A Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian Participants

CompletedNCT07221084

Crinetics Pharmaceuticals Inc.Healthy Volunteers

Start: 2025-10-28End: 2026-02-27Updated: 2026-03-11

Drug-Drug Interaction Study of Atumelnant in Healthy Participants

CompletedNCT07570082

Crinetics Pharmaceuticals Inc.Healthy Volunteers

Start: 2026-05-28End: 2026-07-30Updated: 2026-08-19

Phase 2

A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)

RecruitingNCT07159841

Crinetics Pharmaceuticals Inc.Classic Congenital Adrenal Hyperplasia, Congenital Adrenal Hyperplasia

Start: 2026-01-22End: 2030-03-01Target: 153Updated: 2026-09-02

Phase 3

A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia

RecruitingNCT07144163

Crinetics Pharmaceuticals Inc.Classic Congenital Adrenal Hyperplasia, Congenital Adrenal Hyperplasia

Start: 2025-12-11End: 2027-05-01Target: 150Updated: 2026-09-02

Related Papers

9330 Atumelnant (crn04894) Induces Rapid And Sustained Reductions In Serum And Urine Cortisol In Patients With Acth-Dependent Cushing Syndrome During A Phase 1b/2a, Single Center, 10-day, Inpatient, Open-Label Study

Journal of the Endocrine Society2024-10-013 citations